source
- Health tech firms expand AI scribing tools toward prescribing and billing functionsHealth technology companies are accelerating development of artificial‑intelligence driven scribing solutions that can be deployed across health systems. While early versions focused on documentin…
- Syndax halts development of Niktimvo after Phase 2 failure in IPF trialSyndax announced it is stopping work on its experimental drug Niktimvo for idiopathic pulmonary fibrosis (IPF) after the compound did not meet its primary endpoints in a placebo-controlled Phase 2…